Granted Patent
B2
US 12,691,167 · App. 18/530,348 · Granted Jul 28, 2026
Proteins and immunizing compositions containing
Inventors:
Douglas T. Burkhardt (Dassel, MN); Daryll Emery (New London, MN); Darren Straub (New London, MN)
Assignee:
Vaxxinova US, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are isolated proteins isolatable from a Klebsiella spp. Also provided are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.
Claims (5)
1 . A composition comprising:
an isolated protein comprising an amino acid sequence that has at least 80% identity with SEQ ID NO:41 and an isolated protein comprising an amino acid sequence that has at least 80% identity with SEQ ID NO:42;
an effective amount of an adjuvant; and
a pharmaceutically acceptable carrier.
2 . The composition of claim 1 further comprising a protein comprising an amino acid sequence that has at least 80% identity with SEQ ID NO:45, SEQ ID NO: 46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:58, SEQ ID NO: 61, or SEQ ID NO:64.
Assignments (2)
CHANGE OF NAME
Recorded Mar 14, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066775/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2024
From: BURKHARDT, DOUGLAS; EMERY, DARYLL; STRAUB, DARREN
To: EPITOPIX, LLC
Reel/Frame 066661/0822 →
Continuity (4)
References Cited (92)
US 6027736A
· Emery
· 2000
[cited by applicant]
US 6610836B1
· Breton
· 2003
[cited by applicant]
CA 2029906A1
· 1990
[cited by applicant]
JP 03143388A
· 1991
[cited by applicant]
WO WO9011349
· 1990
[cited by applicant]
WO WO9521627
· 1995
[cited by applicant]
WO WO9601620A1
· 1996
[cited by applicant]
WO WO0137810A2
· 2001
[cited by applicant]
WO WO02053180
· 2002
[cited by applicant]
WO WO2006088803
· 2006
[cited by applicant]
WO WO2008135446
· 2008
[cited by applicant]
WO WO2010111273
· 2010
[cited by applicant]
WO WO2011125015A2
· 2011
[cited by examiner]
McGuinness et al. Lancet 337: 514-517, 1991.
[cited by examiner]
McGuinness et al. McGuiMol. Microbiol. 7: 505-514, 1993.
[cited by examiner]
Pajon et al. Infect. Immun. 80: 2667-2677, 2012.
[cited by examiner]
Ellis RW. Vaccines, (Eds) Plotkin et al., W.B. Saunders Company, Philadelphia, Chapter 29, 568-575, 1988.
[cited by examiner]
PCT Patent Application No. US2016/041614, filed Jul. 8, 2016; International Preliminary Report on Patentability issued Jan. 25, 2018; 15 pages.
[cited by applicant]
PCT Patent Application No. US2016/041614, filed Jul. 8, 2016; International Search Report and Written Opinion issued Mar. 6, 2017; 27 pages.
[cited by applicant]
Baghal et al., Production and Immunogenicity of Recombinant Ferric Enterobactin Protein (FepA),
[cited by applicant]
Biegel Carson et al., “Ferric Enterobactin Binding and Utilization by Neisseria Gonorrhoeae”, Journal of Bacteriology, vol. 181, No. 9, May 1, 1999, pp. 2895-2901.
[cited by applicant]
Bouchet et al., “Immunological Variants of the Aerobactin-Cloacin DF13 Outer Membrane Protein Receptor IUTA Among Enteric Bacteria”,
[cited by applicant]
Boulianne, “Production of functional chimaeric mouse/human antibody” 1984
[cited by applicant]
Brisse, “The genus
[cited by applicant]
Bruggeman, “Production of human antibody repertoires in transgenic mice” 1997
[cited by applicant]
Budzikiewicz, “Siderophore from bacteria and from fungi” in
[cited by applicant]
Chander, “Differentiation of Klebsiella pneumoniae and Klebsiella oxytoca by multiplex poly-merase chain reaction” 2011
[cited by applicant]
Cryz, “Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide” Jan. 1984
[cited by applicant]
Cryz, “Purification and vaccine potential of Klebsiella capsular polysaccharides” 1985
[cited by applicant]
Cryz, “Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development” 1986
[cited by applicant]
Daugherty, “Polymerase chain reaction facilitates the cloning, CDR grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins” 1991
[cited by applicant]
Goujon, “A new bioinformatics analysis tools framework at EMBL-EBI” 2010 Nucleic acids research Jul. 2010, 38 Suppl: W695-9.
[cited by applicant]
Greenspan et al., Nature Biotechnology 17: 936-937, 1999.
[cited by applicant]
Grohn, “Effect of pathogen-specific clinical mastitis on milk yield in dairy cows” 2004
[cited by applicant]
Harlow, Ed.,
[cited by applicant]
Hoblet, “Costs associated with selected preventive practices and with episodes of clinical mastitis in nine herds with low somatic cell counts” Jul. 1991
[cited by applicant]
Hogan et al., “Iron Uptake and Growth Responses by
[cited by applicant]
Houghten et al., New Approaches to Immunization, Vaccine86, Cold Spring Harbor Laboratory, pp. 21-25, 1986.
[cited by applicant]
Jeannin, “Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies” 2002
[cited by applicant]
Jones, “Replacing the complementarity-determining regions in a human antibody with those from a mouse” 1986
[cited by applicant]
Jurkevitch, “Differential Siderophore Utilization and Iron Uptake by Soil and Rhizosphere Bacteria” 1992
[cited by applicant]
Keler, “Metachromatic Assay for the Quantitative Determination of Bacterial Endotoxins” 1986
[cited by applicant]
Kurupati et al., “Identification of Vaccine Candidate Antigens of an ESBL Producing
[cited by applicant]
Kurupati, “Protective Efficacy of DNA Vaccines Encoding Outer Membrane Protein A and OmpK36 of Klebsiella pneumoniae in Mice” Jan. 2011
[cited by applicant]
Lazar et al., Mol. Cellular Biol. 8: 1247-1252, 1988.
[cited by applicant]
Libon, “
[cited by applicant]
Lin et al., “Immunization of Cows with Ferric Enterobactin Receptor from Coliform Bacteria,”
[cited by applicant]
Lin et al., “Inhibition of In Vitro Growth of Coliform Bacteria by a Monoclonal Antibody Directed Against Ferric Enterobactin Receptor FepA”,
[cited by applicant]
Lobuglio, “Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response” Jun. 1989
[cited by applicant]
Lodge, “Influence of Growth Rate and Iron Limitation on the Expression of Outer Membrane Proteins and Enterobactin by Klebsiella pneumoniae Grown in Continuous Culture” Feb. 1986
[cited by applicant]
Lonberg, “Antigen-specific human antibodies from mice comprising four distinct genetic modifications” 1994
[cited by applicant]
Lonberg, “Human Antibodies from Transgenic Mice” 1995
[cited by applicant]
Lundberg, “Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae” 2013,
[cited by applicant]
Lyczak, “Lung infections associated with cystic fibrosis” 2002
[cited by applicant]
Meno, “The Surface Hydrophobicity and Avirulent Character of an Encapsulated Strain of Klebsiella pneumoniae” 1991
[cited by applicant]
Miethke, “Siderophore-based iron acquisition and pathogen control” 2007
[cited by applicant]
Morrison, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” 1984
[cited by applicant]
Murphy et el., “Surface Topology of the
[cited by applicant]
Nikaido, “Outer Membrane” in:
[cited by applicant]
Parchuri, “Extended spectrum beta-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B” 2005
[cited by applicant]
Perkins, “Probability-based protein identification by searching sequence databases using mass spectrometry data” 1999
[cited by applicant]
Pinzon-Sanchez, “Decision tree analysis of treatment strategies for mild and moderate cases of clinical mastitis occurring in early lactation” 2011
[cited by applicant]
Podschun, “
[cited by applicant]
Queen, “A humanized antibody that binds to the interleukin 2 receptor” 1989
[cited by applicant]
Rabsch, “Role of Receptor Proteins for Enterobactin and 2,3-Dihydroxybenzoylserine in Virulence of
[cited by applicant]
Riechmann, “Reshaping human antibodies for therapy” 1988
[cited by applicant]
Roberts et al., “Inhibition of Biological Activities of the Aerobactin Receptor Protein in Rough Strains of
[cited by applicant]
Rudinger et al., In: Peptide Hormones. (Ed) JA Parsons, University Park Press, pp. 1-7, 1979.
[cited by applicant]
Sanchez, Jan. 2013
[cited by applicant]
Shand, “In Vivo Evidence That Bacteria in Urinary Tract Infection Grow Under Iron-Restricted Conditions” Apr. 1985
[cited by applicant]
Sievers, “Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega”
[cited by applicant]
Skolnick et al., Trends in Biotechnology, 18: 34-39, 2000.
[cited by applicant]
Stamm, “Comparison of endemic and epidemic nosocomial infections” in Dixon (ed.),
[cited by applicant]
Tatusova, “Blast 2 Sequences, a new tool for comparing protein and nucleotide sequences” 1999
[cited by applicant]
Taylor, “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins” Dec. 1992
[cited by applicant]
Toky, “Establishment of a sepsis model following implantation of Klebsiella pneumoniae-infected fibrin clot into the peritoneal cavity of mice” 2003
[cited by applicant]
Traxler. “Interspecies modulation of bacterial development through iron competition and siderophore piracy” Nov. 2012
[cited by applicant]
Tuntufye et al.,
[cited by applicant]
Ueda, “In Vitro and In Vivo Antibacterial Activities of SM-216601, a New Broad-Spectrum Parenteral Carbapenem” Oct. 2005
[cited by applicant]
Vered, “Susceptibility to klebsiella pneumonaie infection in collaborative cross mice is a complex trait controlled by at least three loci acting at different time points” 2014,
[cited by applicant]
Verhoeyen, “Reshaping human antibodies: grafting an antilysozyme activity” 1988
[cited by applicant]
Watson, Ed.,
[cited by applicant]
Williams, “Expression of high affinity iron uptake systems by clinical isolates of Klebsiella” Nov. 1987
[cited by applicant]
Wolf et al., “Iron Uptake by
[cited by applicant]
Wu, “Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan” 2005
[cited by applicant]
Yadav, “Lipopolysaccharide-mediated protection againstKlebsiella pneumoniae-induced lobar pneumonia: Intranasalvs. intramuscular route of immunization” Jan. 2005
[cited by applicant]
Yu, “Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections” 2007
[cited by applicant]
Zhou et al., “Binding Characterization of the Iron Transport Receptor from the Outer Membrane of
[cited by applicant]
Chu et al., “Siderphore Uptake in Bacteria and the Battle for Iron with the Host; a Bird's Eye View,” Biometals (2010) 23:601-611.
[cited by applicant]
Office Action issued in Mexico for Application No. MX/a/2018/000395 dated Aug. 22, 2022 (7 pages).
[cited by applicant]